Emerging Infectious Disease Diagnostics Market Report 2026

The emerging infectious disease diagnostics market size has grown strongly in recent years. It will grow from $24.34 billion in 2025 to $26.75 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to increasing frequency of infectious disease outbreaks, expansion of public health surveillance programs, rising investments in laboratory infrastructure, growing demand for rapid diagnostic solutions, advancements in molecular testing technologies.

The emerging infectious disease diagnostics market size is expected to see strong growth in the next few years. It will grow to $38.54 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to increasing focus on pandemic preparedness, rising adoption of next-generation sequencing diagnostics, expansion of decentralized testing models, growing integration of ai-driven diagnostic analytics, increasing government funding for disease monitoring. Major trends in the forecast period include increasing deployment of rapid molecular diagnostic platforms, rising adoption of point-of-care testing solutions, growing integration of genomic surveillance tools, expansion of multiplex diagnostic assays, enhanced focus on early outbreak detection.

The increasing prevalence of zoonotic diseases is expected to drive the growth of the emerging infectious disease diagnostics market in the coming years. Zoonotic diseases are infections that can be transmitted from animals to humans and are caused by bacteria, viruses, parasites, or fungi. The rising incidence of these diseases is largely attributed to factors such as increased human-wildlife interaction, habitat destruction, and global travel, which facilitate cross-species pathogen transmission. Emerging infectious disease diagnostics play a critical role in managing zoonotic diseases by enabling early detection and accurate identification of pathogens, allowing for timely intervention, effective treatment, and better containment of outbreaks, thereby reducing transmission from animals to humans. For example, in June 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, 48 states and the District of Columbia reported 2,770 human arboviral disease cases in 2023, up from 1,247 cases in 2022. Of these, 2,022 cases (73%) required hospitalization, and 208 deaths (8%) were reported, with West Nile virus being the most commonly reported domestic arboviral disease, accounting for 2,628 cases (95%). Thus, the rising incidence of zoonotic diseases is driving the emerging infectious disease diagnostics market.

Key companies in the emerging infectious disease diagnostics market are focusing on innovative solutions, such as temperature-activated generation of signal (TAGS) technology, to enable rapid detection, high-throughput screening, and enhanced outbreak response. TAGS is an advanced multiplex PCR method that uses controlled temperature activation to produce optical signals, allowing the simultaneous identification of multiple pathogens from a single sample. This approach supports broad syndromic testing, faster turnaround times, and more efficient laboratory workflows. For instance, in September 2024, F. Hoffmann-La Roche AG, a Switzerland-based diagnostics and biotechnology company, launched the cobas Respiratory flex test, a TAGS-powered molecular diagnostic capable of detecting up to 12 common respiratory viruses from a single patient sample. The system features automated high-throughput analysis, flexible pathogen panel configuration, and compatibility with cobas 5800, 6800, and 8800 platforms, improving timely detection of infectious agents, strengthening clinical decision-making, and supporting preparedness for emerging disease threats.

In May 2024, Bruker Corporation, a US-based provider of scientific instruments and diagnostic solutions, acquired ELITechGroup for $942 million (€870 million). Through this acquisition, Bruker gained access to ELITech’s “sample to answer” molecular diagnostics platforms, including InGenius and BeGenius, along with a broad infectious disease assay portfolio. This acquisition strengthens Bruker’s molecular diagnostics and in vitro diagnostics capabilities while expanding its presence in hospital and clinical laboratory infectious disease testing globally. ELITechGroup is a France-based in vitro diagnostics company specializing in molecular diagnostics, biomedical systems, and microbiology.

Major companies operating in the emerging infectious disease diagnostics market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMérieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., DiaSorin S.p.A., Randox Laboratories Ltd., Meridian Bioscience Inc., Sekisui Diagnostics LLC, Copan Diagnostics, Co-Diagnostics Inc., T2 Biosystems Inc.

North America was the largest region in the emerging infectious disease diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emerging infectious disease diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the emerging infectious disease diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the emerging infectious disease diagnostics market by increasing costs of imported reagents, diagnostic instruments, sequencing platforms, and electronic components used in molecular and immunodiagnostic systems. Diagnostic laboratories and hospitals in North America and Europe are most affected due to dependence on imported technologies, while Asia-Pacific faces higher costs for large-scale diagnostic deployments. These tariffs are elevating testing costs and affecting procurement timelines. However, they are also promoting domestic production of diagnostic kits, regional manufacturing of testing platforms, and stronger local supply chains for critical diagnostic technologies.

The emerging infectious disease diagnostics market research report is one of a series of new reports that provides emerging infectious disease diagnostics market statistics, including emerging infectious disease diagnostics industry global market size, regional shares, competitors with a emerging infectious disease diagnostics market share, detailed emerging infectious disease diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the emerging infectious disease diagnostics industry. This emerging infectious disease diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Emerging infectious disease diagnostics refers to advanced tools and methods used to detect new or re-emerging infectious diseases caused by pathogens such as viruses, bacteria, or parasites. These diagnostics employ cutting-edge technologies, including molecular testing, genomics, and rapid assays, to identify infections quickly and accurately, thereby enhancing public health responses. They are essential for monitoring and controlling outbreaks and for supporting the development of targeted treatments and vaccines.

The primary infection types addressed by emerging infectious disease diagnostics include viral, bacterial, fungal, and others. Viral infections are caused by viruses, which are microscopic pathogens that replicate inside host cells, and include conditions such as respiratory infections, gastrointestinal infections, and sexually transmitted infections (STIs). Key diagnostic technologies include polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), immunodiagnostics, and others. Applications encompass laboratory testing and point-of-care testing, with end users including hospitals and clinics, diagnostic laboratories, and other healthcare facilities.

The emerging infectious disease diagnostics market consists of revenues earned by entities by providing services such as laboratory testing, diagnostic tool development, clinical interpretation of test results, surveillance and reporting, and the provision of telehealth consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The emerging infectious disease diagnostic market also includes sales of rapid test kits, polymerase chain reaction (PCR) machines, molecular diagnostic assays, sequencing platforms, point-of-care diagnostic devices, and biosensors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.